Clinical research from the Florida Cancer Specialists & Research Institute (FCS) took center stage at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego. The meeting brought together global experts in cancer science and medicine to share the latest advancements in the field.
FCS logo
FCS’s extensive clinical trials program plays a crucial role in the global fight against cancer, improving patient outcomes and quality of life. With access to over 160 clinical trials across 32 clinics and three Drug Development Units in Florida, FCS is at the forefront of cancer research. Many recently approved cancer drugs in the U.S. underwent clinical trials with FCS participation.
Doctors discussing treatment
FCS Research Highlights at AACR 2024
FCS physician investigators presented their findings in both oral and poster sessions. The presented abstracts cover a wide range of innovative cancer therapies and research areas.
Key Research Presented by FCS Physicians
Dr. Manish Patel, FCS Director of Drug Development, co-authored nine abstracts, including studies on:
- KVA12123, a novel VISTA-targeting IgG1, in combination with pembrolizumab for advanced solid tumors.
- AC699, an oral estrogen receptor degrader, for advanced or metastatic breast cancer.
- OSEMITAMAB, alone and in combination with nivolumab, for locally advanced or metastatic solid tumors.
- mRNA-4157 (V940) individualized neoantigen therapy with pembrolizumab for HPV-negative head and neck cancer.
- AC676, a BTK chimeric degrader, for relapsed and refractory B-cell malignancies.
- KO-2806, a farnesyl transferase inhibitor, for advanced solid tumors.
- DS-3939a, a DXd antibody-drug conjugate targeting TA-MUC1, for advanced solid tumors.
- Intratumoral mRNA-2752 encoding human OX40L/IL-23/IL-36γ with durvalumab for advanced solid tumors.
- Pharmacokinetic/biomarker analysis of the TLR7/8 agonist EIK1001 in solid tumors.
Dr. Judy Wang, FCS Associate Director of Drug Development, presented preliminary results from a study on NGM707 combined with pembrolizumab in advanced or metastatic solid tumors.
Dr. Lowell Hart, FCS Scientific Director of Research, presented research on vitamin D deficiency and outcomes in prostate cancer patients. This study utilized a real-world database.
Dr. Cesar Augusto Perez, FCS Director of Drug Development, Lake Nona DDU, co-authored research on SGN-CEACAM5C in adults with advanced solid tumors.
Dr. Bradley Monk, FCS Director of Late-Phase Clinical Research, co-authored a study on tumor microenvironment biomarkers in cervical cancer. This research was conducted prior to his appointment at FCS.
Impact of FCS Research
FCS’s dedication to clinical trials research continues to drive breakthroughs in cancer treatment, leading to a deeper understanding of the disease and transforming the standard of care for patients. The abstracts presented at the AACR Annual Meeting will be published in the journal Cancer Research.
Collaboration and the Future of Cancer Research
Collaboration is key to advancing cancer research and finding effective treatments. FCS’s participation in these global efforts underscores its commitment to improving the lives of cancer patients and their families. For personalized treatment plans, consult with a healthcare professional today.
